Novo Nordisk A/S found using ticker (NVO) have now 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 135.42 and 120.73 calculating the average target price we see 128.98. Given that the stocks previous close was at 115.96 this is indicating there is a potential upside of 11.2%. The 50 day MA is 111.66 and the 200 day moving average is 106.35. The market cap for the company is $255,636m. Company Website: https://www.novonordisk.com
The potential market cap would be $284,339m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
